Merck KGaA (MRK) Given a €120.00 Price Target by UBS Analysts

Merck KGaA (FRA:MRK) has been assigned a €120.00 ($142.86) price objective by equities research analysts at UBS in a research report issued on Wednesday. The brokerage currently has a “buy” rating on the healthcare company’s stock. UBS’s price target would indicate a potential upside of 36.52% from the stock’s previous close.

MRK has been the subject of several other reports. J P Morgan Chase & Co set a €100.00 ($119.05) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Friday, October 6th. Citigroup set a €123.00 ($146.43) price target on shares of Merck KGaA and gave the company a “buy” rating in a research report on Monday, September 25th. Oddo Bhf set a €125.00 ($148.81) price target on shares of Merck KGaA and gave the company a “buy” rating in a research report on Friday, November 10th. Goldman Sachs Group set a €105.00 ($125.00) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Tuesday, September 19th. Finally, Kepler Capital Markets set a €119.00 ($141.67) price target on shares of Merck KGaA and gave the company a “buy” rating in a research report on Thursday, September 21st. Twelve research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average target price of €107.81 ($128.34).

Shares of Merck KGaA (FRA MRK) opened at €87.90 ($104.64) on Wednesday. Merck KGaA has a 1 year low of €87.33 ($103.96) and a 1 year high of €115.00 ($136.90).

COPYRIGHT VIOLATION NOTICE: “Merck KGaA (MRK) Given a €120.00 Price Target by UBS Analysts” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3080864/merck-kgaa-mrk-given-a-120-00-price-target-by-ubs-analysts.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.